The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.

The 3 + 3 design is the most common choice among clinicians for phase I dose-escalation oncology trials. In recent reviews, more than 95% of phase I trials have been based on the 3 + 3 design. Given ...

Pew Research Center’s international surveys are largely conducted via telephone or face-to-face interviews, depending on the country. (The exceptions are the United States and Australia, where surveys ...